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Chronic obstructive pulmonary disease (COPD) is characterized by both local
and systemic manifestations of inflammation. In particular, increased
numbers of neutrophils can be observed in the airway lumen and in the
blood of COPD patients. One early study on patients with COPD and chronic
bronchitis showed increasing levels of the neutrophil product myeloperox-
idase (MPO) during exacerbations, compared with control smokers who did
not suffer from COPD.1 In a more recent study on chronic smokers without
severe airway symptoms, we showed that the MPO concentrations in blood
increases during a six year-period.2 Thus, systemic neutrophil mobilization
may occur prior to the clinical manifestation of COPD.
Here, we determined whether MPO concentration in blood is altered during
exacerbations and/or during stable conditions in COPD patients with chronic
bronchitis (COPD-CB). We studied 60 well-defined COPD patients, 10
asymptomatic smokers and 10 healthy non-smokers. Blood samples were
harvested and analyzed for MPO every 15th week during 15 months and at ex-
acerbations. We also examined if the transcription of MPO is altered in blood
cells from COPD-CB patients.
The study shows that MPO protein and neutrophil concentrations but not MPO
mRNA increasedmarkedlyduringexacerbations inCOPD-CBpatients.Wedidnot
detect any correlation between mRNA and MPO protein during exacerbations.
Tentatively, our study indicates that there is increased release of MPO in
circulating or extravascular neutrophils during COPD exacerbations, and that
a post-transcriptional mechanism for MPO release is feasible.
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Pulmonary hypertension (PH) is a serious complication to chronic obstructive
pulmonary disease (COPD). For early detection, we evaluated predictors of
mean pulmonary artery pressure (mPAP) and PH (mPAP25mmHg).
Altogether 97 COPD patients with mild to very severe airway obstruction
without left ventricle dysfunction were included. Pulmonary function tests,
right heart catheterizations and cardiopulmonary exercise tests (CPET) were
performed.
Multivariate analysis in a model including pulmonary function indices at rest,
adjusted for gender, age and height, showed that only PaO2 was a significant
predictor of mPAP (Regr. coeff. -2.35, 95% CI -3.02,-1.67, p<0.001). Indices
of airway obstruction and hyperinflation failed to predict mPAP. Logistic
regression analysis confirmed that only PaO2 was a significant predictor of
PH (p<0.001). ROC curve analyses with optimal cut-off values for PaO2 at
rest and at peak exercise were applied to test their diagnostic accuracy
for PH. For PaO2 at rest, area under the curve (AUC) was 0.78 (95% CI
0.67, 0.87) and cut-off value  9.5 kPa. For PaO2 at peak exercise, AUC
was 0.81 (95% CI 0.70, 0.93) and cut-off value  8.5 kPa. By combining
PaO2 at rest and peak exercise, pulmonary hypertension was possible to pre-
dict with a detection rate of 76% and a false-positive rate of 10%. When vari-
ables from CPET were included in multiple regression analyses, mPAP was
predicted by oxygen uptake, ventilation and PaO2 at peak exercise (p<0.05).
Conclusion: PaO2 at rest and PaO2 at peak exercise are important to eval-
uate when assessing the presence of PH in COPD.
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Fibrotic events participate in pathogenesis of chronic obstructive pulmonary
disease (COPD) (1). Our aim was to study the expression of alpha-smooth
muscle actin (a-SMA), tenascin-C and EDA-fibronectin in emphysema and
COPD.
Lung tissue specimens from central bronchi and peripheral lung tissue were
analyzed by immunohistochemistry. Number of a-SMA (as a marker of
myofibroblast), tenascin-C and EDA-fibronectin positive areas in alveolar
walls, bronchioles and bronchi were counted in the patients with normal
